Brussels, Brussels Hoofdstedelijk Gewest, Belgium SFPI-FPIM is the famous VC, which was founded in 2006. The main office of represented VC is situated in the Brussels. The company was established in Europe in Belgium.
The fund is generally included in 2-6 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. The higher amount of exits for fund were in 2019. Considering the real fund results, this VC is 10 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2018. Opposing the other organizations, this SFPI-FPIM works on 24 percentage points less the average amount of lead investments.
The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the SFPI-FPIM, startups are often financed by Capricorn Venture Partners, S.R.I.W., BioMedPartners. The meaningful sponsors for the fund in investment in the same round are Capricorn Venture Partners, PMV, Meusinvest. In the next rounds fund is usually obtained by S.R.I.W., Vesalius Biocapital Partners, Gimv.
Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Belgium. The fund has exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the most popular portfolio startups of the fund, we may highlight iSTAR Medical, Miracor Medical, ITeos Therapeutics. Among the most successful fund investment fields, there are Pharmaceutical, Therapeutics.
Related Funds
| Fund Name | Location |
| AddVentures by SCG | Bangkok, Krung Thep, Thailand |
| AES | United States, Virginia, Virginia Beach |
| AIG Highstar Capital | New York, New York, United States |
| Anhuisheng Renhua Qiye Guanli Zixun Youxian Gongsi | Anhui, China, Hefei |
| Blackberrys | Gurgaon, Haryana, India |
| Capitec Bank | South Africa, Stellenbosch, Western Cape |
| Consor Capital | California, Sausalito, United States |
| Deportare Partners | Japan, Tokyo |
| Enjoyor | China, Hangzhou, Zhejiang |
| Lit Cheong Power Engineering | China, Guangdong, Shenzhen |
| Nasdaq Ventures | Maryland, Rockville, United States |
| Orion Corporation | Espoo, Finland, Uusimaa |
| Rankong Touzi | China, Hangzhou, Zhejiang |
| Siemens Mustang Ventures | California, Santa Clara, United States |
| Spring Activator | British Columbia, Canada, Vancouver |
| Sumitomo Corporation Equity Asia | China, Hong Kong, Hong Kong Island |
| TAISEI | Japan, Tokyo |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Tangent Works | $4M | 15 Dec 2022 | Belgium, Flemish Brabant, Belgium | ||
Cohabs | $82M | 16 Nov 2022 | Brussels, Brussels Hoofdstedelijk Gewest, Belgium | ||
Axelera AI | $27M | 25 Oct 2022 | Eindhoven, Noord-Brabant, The Netherlands | ||
PDC*line Pharma | $13M | 06 Dec 2021 | France, Auvergne-Rhône-Alpes, France | ||
Qpinch | $16M | 09 Sep 2021 | Antwerpen, Antwerp, Belgium | ||
Imcyse | $25M | 17 Feb 2021 | Liège, Liège, Belgium | ||
Univercells | $23M | 17 Dec 2020 | Charleroi, Hainaut, Belgium | ||
ExeVir Bio | $49M | 28 Jul 2020 | Ghent, East Flanders, Belgium | ||
ITeos Therapeutics | $125M | 01 Apr 2020 | Cambridge, Massachusetts, United States |
– ExeVir from Ghent, Belgium develops single domain antibody therapies providing broad protection against viral infections.
– The company closed its Series A financing raising a total of US$50m.
– Led by Fund+, the round was also joined by VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest as well as several Belgian family offices.
– The company is using the funds to commence the global phase 1b/2 clinical trial of lead compound XVR011 and develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
– ExeVir closed its Series A financing raising a total of EUR 42 million / US$50 million.
– The financing was led by Fund++ with VIB, UCB Ventures, SFPI-FPIM, V-Bio Ventures and new investors SRIW, Noshaq, Vives IUF, SambrInvest, as well as several Belgian family offices.
– ExeVir will use the financing to commence the global phase 1b/2 clinical trial of lead compound XVR011 that is scheduled to start shortly.
– The company also plans to develop a VHH72-Fc sub-cutaneous formulation for Covid-19 in parallel and accelerate development of its pipeline beyond Covid-19 in infectious diseases.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Tangent Works | $4M | 15 Dec 2022 | Belgium, Flemish Brabant, Belgium | ||
Cohabs | $82M | 16 Nov 2022 | Brussels, Brussels Hoofdstedelijk Gewest, Belgium | ||
Axelera AI | $27M | 25 Oct 2022 | Eindhoven, Noord-Brabant, The Netherlands | ||
PDC*line Pharma | $13M | 06 Dec 2021 | France, Auvergne-Rhône-Alpes, France | ||
Qpinch | $16M | 09 Sep 2021 | Antwerpen, Antwerp, Belgium | ||
Imcyse | $25M | 17 Feb 2021 | Liège, Liège, Belgium | ||
Univercells | $23M | 17 Dec 2020 | Charleroi, Hainaut, Belgium | ||
ExeVir Bio | $49M | 28 Jul 2020 | Ghent, East Flanders, Belgium | ||
ITeos Therapeutics | $125M | 01 Apr 2020 | Cambridge, Massachusetts, United States |
